212142-18-2

212142-18-2 structure

Name: Vatalanib succinate
Chemical Name: butanedioic acid,N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine
CAS Number: 212142-18-2
Molecular Formula: C₂₄H₂₁ClN₄O₄
Molecular Weight: 464.90
Catalog: Signaling Pathways Protein Tyrosine Kinase/RTK VEGFR
Create Date: 2018-09-15 16:26:29
Modify Date: 2024-01-29 19:13:29
Vatalanib (PTK787) succinate is a potent and orally active VEGFR inhibitor with IC50s of 37 nM, 77 nM, 270 nM, 660 nM, 730 nM, 1400 nM, and 580 nM for KDR, Flt-1, Flk, Flt-4, c-Kit, c-Fms, and PDGFR-β, respectively[1].

Name	butanedioic acid,N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine
Synonyms	N-(4-Chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine, butanedioate (1:1) PTK787 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine succinate Succinic acid - N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine (1:1) 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-, butanedioate (1:1) N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine succinate N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine succinate (1:1) (4-Chlorophenyl)[4-(pyridin-4-ylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine butanedioate (1:1) (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate Vatalanib T66 CNNJ BMR DG& E1- DT6NJ &&Succinate Vatalanib succinate PTK/ZK

Description	Vatalanib (PTK787) succinate is a potent and orally active VEGFR inhibitor with IC50s of 37 nM, 77 nM, 270 nM, 660 nM, 730 nM, 1400 nM, and 580 nM for KDR, Flt-1, Flk, Flt-4, c-Kit, c-Fms, and PDGFR-β, respectively[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Protein Tyrosine Kinase/RTK >> VEGFR
Target	KDR:37 nM (IC50) Flt-1:77 nM (IC50) Flt-4:730 nM (IC50)
References	[1]. J M Wood, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 2000 Apr 15;60(8):2178-89.